AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29470691 — intervention group
Group type: EXPERIMENTAL
Intervention: Caseinate (CAS)
Number of subjects: 27
Study 29470691 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CHO)
Number of subjects: 27
Study 29798253 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative inflatable heating blanket (A group, n=20)
Number of subjects: 60
Study 29798253 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed irrigation (B group, n=20)
Number of subjects: 60
Study 29798253 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group, n=20)
Number of subjects: 60
Study 25959002 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) chemotherapy
Number of subjects: 125
Study 25959002 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chemotherapy
Number of subjects: 125
Study 25959002 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall chemotherapy (both IV and oral)
Number of subjects: 125
Study 23331924 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cerclage with cervical occlusion
Number of subjects: 309
Study 23331924 — intervention group
Group type: COMPARATOR
Intervention: Cervical cerclage without cervical occlusion
Number of subjects: 309
Study 23331924 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical occlusion with cerclage
Number of subjects: 309
Study 21726499 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindox® 150 mg capsule (test)
Number of subjects: 24
Study 21726499 — intervention group
Group type: COMPARATOR
Intervention: Dalacin C® 150 mg capsule (reference)
Number of subjects: 24
Study 19531217 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg/day)
Number of subjects: 411
Study 19531217 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 411
Study 16707074 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional antipsychotic drugs
Number of subjects: 363
Study 16707074 — intervention group
Group type: COMPARATOR
Intervention: New atypical drugs
Number of subjects: 363
Study 16707074 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 363
Study 16707074 — intervention group
Group type: COMPARATOR
Intervention: New atypical drugs (band 2)
Number of subjects: 363
Study 15531010 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 NaP tablets (1.5 g NaP/tablet) each morning for 28 days (group A)
Number of subjects: 43
Study 15531010 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 NaP tablets (1.5 g NaP/tablet) each morning for 28 days (group B)
Number of subjects: 43
Study 11747148 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Fr catheters
Number of subjects: 410
Study 11747148 — intervention group
Group type: COMPARATOR
Intervention: 6 Fr catheters
Number of subjects: 410
Study 9430569 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision technique
Number of subjects: 40
Study 9430569 — intervention group
Group type: COMPARATOR
Intervention: Two-incision technique
Number of subjects: 40
Study 9430569 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 40
Study 7986979 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP-2200 (automatic non-invasive arterial pressure monitor)
Number of subjects: 86
Study 7986979 — intervention group
Group type: COMPARATOR
Intervention: Manual apparatus (mercury sphygmomanometer)
Number of subjects: 86
Study 2900351 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening by clinical examination of the breast with mammography in alternate years for 45,841 women
Number of subjects: 127117
Study 2900351 — intervention group
Group type: COMPARATOR
Intervention: Teaching in breast self‐examination for 63,636 women
Number of subjects: 127117
Study 2900351 — intervention group
Group type: COMPARATOR
Intervention: Comparison population of 127,117 women with no extra services provided
Number of subjects: 127117
Study 25907673 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxidopa (200 to 600 mg TID)
Number of subjects: 20
Study 25907673 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxidopa plus Carbidopa (25 or 50 mg TID)
Number of subjects: 20
Study 25907673 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-treatment (Droxidopa + Carbidopa)
Number of subjects: 20
Study 25907673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28074482 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 6
Study 28074482 — intervention group
Group type: COMPARATOR
Intervention: Control (no RIPC)
Number of subjects: 6
Study 26234543 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Adjusting File (SAF; ReDent-Nova)
Number of subjects: 48
Study 26234543 — intervention group
Group type: EXPERIMENTAL
Intervention: Twisted File Adaptive (TFA; SybronEndo)
Number of subjects: 48
Study 26234543 — intervention group
Group type: EXPERIMENTAL
Intervention: Twisted File Adaptive (TFA) with Passive Ultrasonic Irrigation (PUI)
Number of subjects: 48
Study 26234543 — intervention group
Group type: COMPARATOR
Intervention: Self-Adjusting File (SAF)
Number of subjects: 48
Study 23142449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic-on-ceramic bearing (CERAMIC), n = 48
Number of subjects: 92
Study 23142449 — intervention group
Group type: COMPARATOR
Intervention: Ceramic-on-highly-crosslinked-polyethylene bearing (POLYETHYLENE), n = 44
Number of subjects: 92
Study 23142449 — intervention group
Group type: COMPARATOR
Intervention: Ceramic-on-highly-crosslinked-polyethylene bearing (POLYETHYLENE)
Number of subjects: 92
Study 23142449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic-on-ceramic bearing (CERAMIC)
Number of subjects: 92
Study 21173013 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (2 mg/kg subcutaneous daily, maximum 100 mg)
Number of subjects: 24
Study 21173013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21173013 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 24
Study 18294480 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss > 5%
Number of subjects: 1706
Study 18294480 — intervention group
Group type: COMPARATOR
Intervention: Weight loss <= 5%
Number of subjects: 1706
Study 18294480 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change (not specified)
Number of subjects: 1706
Study 16172149 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hLH (lutropin alfa) 75 IU s.c. plus r-hFSH
Number of subjects: 114
Study 16172149 — intervention group
Group type: COMPARATOR
Intervention: r-hFSH alone
Number of subjects: 114
Study 12563620 — intervention group
Group type: COMPARATOR
Intervention: Neoral (cyclosporine) alone
Number of subjects: 7
Study 12563620 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (cyclosporine) with olestra (0.35 g/kg, max 16 g)
Number of subjects: 7
Study 10694769 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral iron supplementation (2-3 mg of elemental iron per kg of body weight) for 3 months
Number of subjects: 163
Study 10694769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 10694769 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral iron supplementation
Number of subjects: 163
Study 9181765 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (group I)
Number of subjects: 113
Study 9181765 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (group II)
Number of subjects: 113
Study 8451344 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational-Emotive Therapy
Number of subjects: 141
Study 8451344 — intervention group
Group type: COMPARATOR
Intervention: Auditory subliminal stimulation
Number of subjects: 141
Study 8451344 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Rational-Emotive Therapy + Auditory subliminal stimulation)
Number of subjects: 141
Study 8451344 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 141
Study 3488384 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3 daily (group +D)
Number of subjects: 40
Study 3488384 — intervention group
Group type: COMPARATOR
Intervention: Control group (group -D)
Number of subjects: 40
Study 29804929 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine or risperidone
Number of subjects: 694
Study 29804929 — intervention group
Group type: EXPERIMENTAL
Intervention: ABLs below RR
Number of subjects: 694
Study 29804929 — intervention group
Group type: EXPERIMENTAL
Intervention: ABLs within/above RR
Number of subjects: 694
Study 26584454 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Careless™
Number of subjects: 10
Study 26584454 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg Careless™
Number of subjects: 10
Study 26584454 — intervention group
Group type: EXPERIMENTAL
Intervention: Careless™ (3000 µg/mL)
Number of subjects: 10
Study 26584454 — intervention group
Group type: EXPERIMENTAL
Intervention: Careless™ (1500 µg/mL)
Number of subjects: 10
Study 26584454 — intervention group
Group type: EXPERIMENTAL
Intervention: Careless™ (300 µg/mL)
Number of subjects: 10
Study 23746264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean UFC levels from samples 1 and 2
Number of subjects: 152
Study 23746264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean UFC levels from samples 3 and 4
Number of subjects: 152
Study 23746264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapatient coefficient of variation (CV) for mUFC using all four samples
Number of subjects: 152
Study 23746264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapatient CV for samples 1 and 2
Number of subjects: 152
Study 23746264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapatient CV for samples 3 and 4
Number of subjects: 152
Study 23746264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapatient CV for samples 1, 2, and 3
Number of subjects: 152
Study 23746264 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in mUFC
Number of subjects: 152
Study 23746264 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between UFC and clinical features of hypercortisolism
Number of subjects: 152
Study 23534775 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron injection as primary prophylaxis
Number of subjects: 96
Study 23534775 — intervention group
Group type: COMPARATOR
Intervention: Non-granisetron group
Number of subjects: 96
Study 21221620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection (ITDI) - 4 sequential injections within 2 weeks after systemic steroids
Number of subjects: 46
Study 21221620 — intervention group
Group type: COMPARATOR
Intervention: Control group - no further medications after systemic steroids
Number of subjects: 46
Study 18320015 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump surgery
Number of subjects: 40
Study 18320015 — intervention group
Group type: COMPARATOR
Intervention: Off-pump surgery
Number of subjects: 40
Study 18320015 — intervention group
Group type: EXPERIMENTAL
Intervention: Both on-pump and off-pump surgery
Number of subjects: 40
Study 17205816 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with cervical plexus block (CPB)
Number of subjects: 60
Study 17205816 — intervention group
Group type: COMPARATOR
Intervention: Cervical plexus block (CPB) alone
Number of subjects: 60
Study 14664881 — intervention group
Group type: EXPERIMENTAL
Intervention: Arimidex (anastrozole) alone or in combination with tamoxifen
Number of subjects: 285
Study 14664881 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 285
Study 10809459 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU stays of 14 days or longer
Number of subjects: 1494
Study 10809459 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of care preferences with physicians
Number of subjects: 1494
Study 10809459 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients preferring palliative care
Number of subjects: 1494
Study 10809459 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with long ICU stays
Number of subjects: 1494
Study 8776638 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin management (100 IU/kg i.v. and 0 to 1,000 IU/L priming; target ACT over 180 seconds)
Number of subjects: 24
Study 8776638 — intervention group
Group type: COMPARATOR
Intervention: High-dose heparin management (300 IU/kg i.v. and 5,000 IU/L priming; target ACT over 480 seconds)
Number of subjects: 24
Study 1595228 — intervention group
Group type: EXPERIMENTAL
Intervention: EHRZ regimen
Number of subjects: 178
Study 1595228 — intervention group
Group type: EXPERIMENTAL
Intervention: SHRZ regimen
Number of subjects: 178
Study 1595228 — intervention group
Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 178
Study 6429872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous feeding with amino acid dextrose solutions and fat emulsions
Number of subjects: 34
Study 6429872 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care (unfed group)
Number of subjects: 34
Study 6429872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous feeding
Number of subjects: 34
Study 31655622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5-10 mg/day
Number of subjects: 38
Study 31655622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 28251811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 244
Study 28251811 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.7 mg
Number of subjects: 244
Study 26761395 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Ring Isolation (SRI)
Number of subjects: 187
Study 26761395 — intervention group
Group type: COMPARATOR
Intervention: Wide Antral Isolation (WAI)
Number of subjects: 187
Study 26761395 — intervention group
Group type: COMPARATOR
Intervention: Comparison between SRI and WAI
Number of subjects: 187
Study 25123605 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Patient Reported Outcomes (PRO) collection
Number of subjects: 47
Study 25123605 — intervention group
Group type: COMPARATOR
Intervention: Paper Patient Reported Outcomes (PRO) collection
Number of subjects: 47
Study 22424026 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) transfusion of ≥4 U
Number of subjects: 1491
Study 22424026 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG-related major bleeding
Number of subjects: 1491
Study 22424026 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic blood product transfusions
Number of subjects: 1491
Study 22424026 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year mortality
Number of subjects: 1491
Study 20383533 — intervention group
Group type: EXPERIMENTAL
Intervention: VAM-solo-surgeon living donor nephrectomy (SLDN)
Number of subjects: 82
Study 20383533 — intervention group
Group type: COMPARATOR
Intervention: Conventional VAM-human-assisted living donor nephrectomy (HLDN)
Number of subjects: 82
Study 17352866 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxia Huayu Decoction
Number of subjects: 53
Study 17352866 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal treatment)
Number of subjects: 53
Study 16229633 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-infrared spectroscopy
Number of subjects: 247
Study 16229633 — intervention group
Group type: EXPERIMENTAL
Intervention: Raman spectroscopy
Number of subjects: 247
Study 16229633 — intervention group
Group type: COMPARATOR
Intervention: Mid-infrared and Raman spectroscopy
Number of subjects: 247
Study 11895165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycasin HBC
Number of subjects: 9
Study 11895165 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogenated polysaccharide fraction of Lycasin HBC
Number of subjects: 9
Study 11895165 — intervention group
Group type: COMPARATOR
Intervention: Dextrose
Number of subjects: 9
Study 9989713 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Training (AT)
Number of subjects: 68
Study 9989713 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy Treatment (PT)
Number of subjects: 68
Study 7774213 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine
Number of subjects: 100
Study 7774213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2148341 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300 mg daily in three divided doses)
Number of subjects: 8
Study 7306966 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamide, 400 mg/sq m; methotrexate, 30 mg/sq m; and 5‐FU, 500 mg/sq m, given i.v. every 2 weeks)
Number of subjects: 62
Study 7306966 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU, 500 mg/sq m i.v. every week)
Number of subjects: 62
Study 31041717 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/nab-paclitaxel (+/- bevacizumab)
Number of subjects: 10
Study 31551226 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol combined with conventional therapy
Number of subjects: 180
Study 31551226 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 180
Study 28041757 — intervention group
Group type: EXPERIMENTAL
Intervention: iGEL supraglottic airway
Number of subjects: 46
Study 28041757 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MAC)
Number of subjects: 46
Study 25932657 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact (CON)
Number of subjects: 19
Study 23701010 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene instruction and supragingival scaling (treatment group, n = 26)
Number of subjects: 55
Study 23701010 — intervention group
Group type: COMPARATOR
Intervention: No periodontal treatment (control group, n = 29)
Number of subjects: 55
Study 21889802 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior or cognitive therapy (16 sessions) with fluvoxamine
Number of subjects: 121
Study 21889802 — intervention group
Group type: COMPARATOR
Intervention: Behavior or cognitive therapy (16 sessions) without fluvoxamine
Number of subjects: 121
Study 19688313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ningdong Granule (NDG) plus haloperidol
Number of subjects: 90
Study 19688313 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol alone
Number of subjects: 90
Study 18637764 — intervention group
Group type: EXPERIMENTAL
Intervention: P. ginseng and warfarin (n = 12)
Number of subjects: 25
Study 18637764 — intervention group
Group type: COMPARATOR
Intervention: Warfarin only (n = 13)
Number of subjects: 25
Study 16131290 — intervention group
Group type: EXPERIMENTAL
Intervention: T/S needles placed in traditional sites with manual needle stimulation (n = 29)
Number of subjects: 114
Study 16131290 — intervention group
Group type: EXPERIMENTAL
Intervention: T/0 traditional needle location without stimulation (n = 30)
Number of subjects: 114
Study 16131290 — intervention group
Group type: EXPERIMENTAL
Intervention: N/S needles inserted in nontraditional locations with stimulation (n = 28)
Number of subjects: 114
Study 16131290 — intervention group
Group type: EXPERIMENTAL
Intervention: N/0 nontraditional needle location without stimulation (n = 27)
Number of subjects: 114
Study 12325097 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10095815 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-morning snack served 2 hours after insulin injection
Number of subjects: 28
Study 10095815 — intervention group
Group type: COMPARATOR
Intervention: No mid-morning snack served
Number of subjects: 28
Study 8530976 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord MRI
Number of subjects: 27
Study 8530976 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain MRI
Number of subjects: 27
Study 8530976 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual EPs
Number of subjects: 27
Study 8530976 — intervention group
Group type: EXPERIMENTAL
Intervention: Median somatosensory EPs
Number of subjects: 27
Study 8530976 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial somatosensory EPs
Number of subjects: 27
Study 8530976 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor EPs
Number of subjects: 27
Study 8530976 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-stem acoustic EPs
Number of subjects: 27
Study 8530976 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF oligoclonal bands (OBs)
Number of subjects: 27
Study 8530976 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term clinical outcome
Number of subjects: 27
Study 8530976 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial somatosensory EP and motor EP abnormalities
Number of subjects: 27
Study 8530976 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term clinical follow-up (mean duration 24 months)
Number of subjects: 27
Study 8530976 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of CSF OBs
Number of subjects: 27
Study 8530976 — intervention group
Group type: EXPERIMENTAL
Intervention: EPs exploring spinal cord function
Number of subjects: 27
Study 8530976 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of brain MRI and CSF OBs
Number of subjects: 27
Study 2192444 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 13
Study 721787 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 36
Study 721787 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 36
Study 31615177 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation combined with selective lumbosacral posterior rhizotomy (SPR)
Number of subjects: 47
Study 31615177 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 47
Study 27740732 — intervention group
Group type: EXPERIMENTAL
Intervention: Four novel mutations identified: DNMT3A rs2304429 (24.74%), CYP1A1 rs3826041 (47.35%), STX1B rs72800847 (7.01%), NQO1 rs10517 (36.11%)
Number of subjects: 1617
Study 27740732 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of four mutations to the regression model
Number of subjects: 1617
Study 27740732 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel mutations identified
Number of subjects: 1617
Study 25484310 — intervention group
Group type: EXPERIMENTAL
Intervention: Stempeucel
Number of subjects: 20
Study 25484310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23384679 — intervention group
Group type: EXPERIMENTAL
Intervention: QbG10
Number of subjects: 63
Study 23384679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 21518924 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔSUVmaxPET0-2 (> 66%)
Number of subjects: 85